SeaStar Medical Developed Breakthrough Selective Cytopheretic Device for Cardiorenal Syndrome

SeaStar Medical has a developed breakthrough cell-directed selective cytopheretic device (SCD) for the treatment of patients in the hospital intensive care unit (ICU) who are suffering from acute or chronic systolic heart failure and worsening renal function due to cardiorenal syndrome or right ventricular dysfunction while awaiting the implantation of a left ventricular assist device (LVAD).

Cardiorenal syndrome is a condition that occurs in the most severe cases of heart failure, where the dysfunction of the heart and kidneys is closely interlinked. This cycle of heart and kidney dysfunction can result in a very poor prognosis for patients.

The selective cytopheretic device (SCD) is a revolutionary approach to combatting hyperinflammation in critically ill patients suffering from chronic heart failure.

The SCD effectively halts the downward spiral often perpetuated by the hyperinflammatory state driven by the overactive innate immune system, offering these patients a newfound opportunity for recovery and improved health.   

Hyperinflammation is characterised by the excessive production and heightened activity of inflammatory cells and molecules within the body. This abnormal immune response can have severe consequences, leading to organ damage, multi-organ failure, and in the most severe cases, it can even result in death.

Unlike traditional methods of pathogen removal and other blood-purification techniques, the Selective Cytopheretic Device (SCD) stands out by its ability to selectively target and address the most highly activated proinflammatory neutrophils and monocytes.